Tiziana Life Sciences (NASDAQ:TLSA) (LON:TILS)'s investment case is presented by Proactive Research Analyst John Savin who explains why the group's recent licensing deal with Precision Biosciences Inc (NASDAQ:DTIL) could become 'a major value add' to Tiziana over the long term.
Savin says Precision Biosciences, Tiziana’s new US partner, is hoping to use foralumab, Tiziana’s clinical-stage fully-human mAb, as a lymphodepletion or ‘tolerising’ agent to improve the long-term success of CAR-T in cancer treatment.
Read Proactive analyst latest update: New use for foralumab in CAR T-cell therapy